These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9521742)

  • 1. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity.
    Turko IV; Francis SH; Corbin JD
    Biochemistry; 1998 Mar; 37(12):4200-5. PubMed ID: 9521742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation.
    Turko IV; Francis SH; Corbin JD
    Biochem J; 1998 Feb; 329 ( Pt 3)(Pt 3):505-10. PubMed ID: 9445376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain.
    Rybalkin SD; Rybalkina IG; Shimizu-Albergine M; Tang XB; Beavo JA
    EMBO J; 2003 Feb; 22(3):469-78. PubMed ID: 12554648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.
    Corbin J; Francis S; Zoraghi R
    Int J Impot Res; 2006; 18(3):251-7. PubMed ID: 16281046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5).
    Stacey P; Rulten S; Dapling A; Phillips SC
    Biochem Biophys Res Commun; 1998 Jun; 247(2):249-54. PubMed ID: 9642111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5).
    Corbin JD; Beasley A; Turko IV; Haik TL; Mangum KA; Wells JN; Francis SH; Sekhar KR
    Cell Biochem Biophys; 1998; 29(1-2):145-57. PubMed ID: 9631243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing domain functions of chimeric PDE6alpha'/PDE5 cGMP-phosphodiesterase.
    Granovsky AE; Natochin M; McEntaffer RL; Haik TL; Francis SH; Corbin JD; Artemyev NO
    J Biol Chem; 1998 Sep; 273(38):24485-90. PubMed ID: 9733741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase.
    Huang D; Hinds TR; Martinez SE; Doneanu C; Beavo JA
    J Biol Chem; 2004 Nov; 279(46):48143-51. PubMed ID: 15331594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5).
    Turko IV; Francis SH; Corbin JD
    J Biol Chem; 1999 Oct; 274(41):29038-41. PubMed ID: 10506154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase.
    Turko IV; Francis SH; Corbin JD
    J Biol Chem; 1998 Mar; 273(11):6460-6. PubMed ID: 9497379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase.
    Liu L; Underwood T; Li H; Pamukcu R; Thompson WJ
    Cell Signal; 2002 Jan; 14(1):45-51. PubMed ID: 11747988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural determinants of the PDE6 GAF A domain for binding the inhibitory gamma-subunit and noncatalytic cGMP.
    Muradov H; Boyd KK; Artemyev NO
    Vision Res; 2004; 44(21):2437-44. PubMed ID: 15358079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
    Corbin JD; Francis SH
    Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
    Turko IV; Ballard SA; Francis SH; Corbin JD
    Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
    Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
    Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial reconstitution of photoreceptor cGMP phosphodiesterase characteristics in cGMP phosphodiesterase-5.
    Granovsky AE; Artemyev NO
    J Biol Chem; 2001 Jun; 276(24):21698-703. PubMed ID: 11285263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
    Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
    J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
    Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.